A court in Indianapolis is expected to issue a ruling today in a drug-patent case that could have a major impact on the way potential investors view the stock of innovative drugmakers versus those that make generics. The court is set to rule at the end of the day on whether Eli Lilly's Zyprexa for treating schizophrenia and bipolar disorder is protected by a valid patent through 2011 or whether Zenith Goldline Pharmaceuticals, Dr. Reddy's Laboratories and Teva Pharmaceutical Industries were correct in asserting the drug's patent is invalid.

Related Summaries